

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 September 2005 (29.09.2005)

PCT

(10) International Publication Number
WO 2005/089741 A3

(51) International Patent Classification⁷: A61K 31/137,
A61P 1/00, 11/00, 11/06, 13/12, 17/00, 17/06, 19/02,
19/10, 25/00, 29/00, 37/00, 43/00

(21) International Application Number:
PCT/GB2005/001031

(22) International Filing Date: 17 March 2005 (17.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0406016.6 17 March 2004 (17.03.2004) GB
0418556.7 19 August 2004 (19.08.2004) GB
0422880.5 14 October 2004 (14.10.2004) GB

(71) Applicant (for all designated States except US): **ARAKIS LTD.** [GB/GB]; Chesterford Research Park, Little Chesterford, Saffron Walden, Essex CB10 1XL (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAXTER, Andrew, Douglas** [GB/GB]; Arakis Ltd., Chesterford Research Park, Little Chesterford, Saffron Walden, Essex CB10 1XL (GB). **BREW, John** [GB/GB]; Arakis Ltd., Chesterford Research Park, Little Chesterford, saffron Walden, Essex CB10 1XL (GB).

(74) Agent: **GILL JENNINGS & EVERY**; Broadgate Hosue, 7 Eldon Street, London EC2M 7LH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

(88) Date of publication of the international search report:
23 March 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN USING BETA-AMINOALCOHOLS



(I)

(57) Abstract: A compound (preferably bufeniode, denopamine, fenoterol, ifenprodil, isoxsuprine, labetalol, medroxalol, mesuprine, nyldrin, protokylol, ractopamine, ritodrine, salmefamol or sulfinalol) that has utility in the treatment or prevention of a condition associated with T-cell proliferation or that is mediated by pro- and/or anti-inflammatory cytokines, and in particular a disease selected from the group consisting of rheumatoid arthritis, osteoarthritis, or osteoporosis, chronic demyelinating disease such as multiple sclerosis, respiratory diseases such as asthma or chronic obstructive pulmonary disease, inflammatory bowel disease (IBD) such as ulcerative colitis or Crohn's disease, dermatological conditions such as psoriasis, scleroderma or atopic dermatitis, dental diseases such as periodontal disease or gingivitis, diabetic nephropathy, lupus nephritis, IgA nephropathy or glomerulonephritis, systemic lupus erythematous (SLE), graft vs host disease, a pain condition, is of formula (I), wherein R₁ is H or Me; R₂ is H or alkyl and R₃ is H or Me, or R₂ and R₃ are -CH₂- thereby forming a ring; n is 0 to 2; X is CH₂ or O; and the two benzene rings are each optionally substituted with OH, OMe, halogen, NHCHO, NHSO₂Me, CONH₂, SOME, OCH₂O, or CH₂OH.

WO 2005/089741 A3

INTERNATIONAL SEARCH REPORT

International Application No

. . . /GB2005/001031

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/137 A61P1/00 A61P11/00 A61P11/06 A61P13/12 A61P17/00 A61P17/06 A61P19/02 A61P19/10 A61P25/00 A61P29/00 A61P37/00 A61P43/00				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K A61P				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, EMBASE, BIOSIS, CHEM ABS Data, WPI Data, BEILSTEIN Data				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	HOLEN E ET AL: "Effects of beta2 adrenoceptor agonists on T-cell subpopulations." APMIS : ACTA PATHOLOGICA, MICROBIOLOGICA, ET IMMUNOLOGICA SCANDINAVICA. SEP 1998, vol. 106, no. 9, September 1998 (1998-09), pages 849-857, XP008051905 ISSN: 0903-4641 the whole document	1		
X	WO 03/092689 A (ARAKIS LTD; BREW, JOHN; BANNISTER, ROBIN, MARK; BAXTER, ANDREW, DOUGLA) 13 November 2003 (2003-11-13) abstract page 1, line 29 - page 3, line 29; claims 1-6 ----- -/--	1,11-16		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;"><input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.</td> <td style="width: 50%; border: none;"><input checked="" type="checkbox"/> Patent family members are listed in annex.</td> </tr> </table>			<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.	<input checked="" type="checkbox"/> Patent family members are listed in annex.
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.	<input checked="" type="checkbox"/> Patent family members are listed in annex.			
° Special categories of cited documents :				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; border: none;"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family </td> </tr> </table>			*A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family			
Date of the actual completion of the international search <p style="text-align: center;">3 November 2005</p>	Date of mailing of the international search report <p style="text-align: center;">18/11/2005</p>			
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer <p style="text-align: center;">A. Jakobs</p>			

INTERNATIONAL SEARCH REPORT

International Application No
/GB2005/001031

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KAMEI T ET AL: "Comparison between fenoterol and fenoterol plus oxitropium bromide delivered by metered-dose inhaler with InspirEase to relieve acute asthma attack." THE JOURNAL OF ASTHMA : OFFICIAL JOURNAL OF THE ASSOCIATION FOR THE CARE OF ASTHMA. 1999, vol. 36, no. 1, 1999, pages 67-75, XP008051909 ISSN: 0277-0903 abstract	1
X	DEY RANJAN ET AL: "Labetalol for prophylactic treatment of intractable migraine during pregnancy." HEADACHE. 2002 JUL-AUG, vol. 42, no. 7, July 2002 (2002-07), pages 642-645, XP008051908 ISSN: 0017-8748 abstract	1
X	TACHIBANA A ET AL: "Inhibition by fenoterol of human eosinophil functions including beta2-adrenoceptor-independent actions." CLINICAL AND EXPERIMENTAL IMMUNOLOGY. DEC 2002, vol. 130, no. 3, December 2002 (2002-12), pages 415-423, XP008051907 ISSN: 0009-9104 abstract	1
A	US 3 542 870 A (JEAN PIERRE FOURNEAU ET AL) 24 November 1970 (1970-11-24) the whole document	1-17
X	WO 02/078670 A (NEURON THERAPEUTICS, INC) 10 October 2002 (2002-10-10) abstract page 3, line 1 - page 5; claims 14,16	1,3,15
X	CHIZH BORIS A ET AL: "Supraspinal vs spinal sites of the antinociceptive action of the subtype-selective NMDA antagonist ifenprodil" NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 40, no. 2, 2001, pages 212-220, XP002192014 ISSN: 0028-3908 the whole document	1,11-13, 15

-/--

INTERNATIONAL SEARCH REPORT

International Application No

/GB2005/001031

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/44610 A (MERCK SHARP & DOHME LIMITED; BOYCE, SUSAN) 10 September 1999 (1999-09-10) page 4, line 30 - page 5, line 26; claims 1,2 abstract	1,11-15, 17
X	WO 99/44640 A (MERCK SHARP & DOHME LIMITED; BOYCE, SUSAN) 10 September 1999 (1999-09-10) abstract page 4, line 29 - page 5, line 23; claims 1,2; table 1	1,2, 11-15,17
X	WO 97/14415 A (F.H. FAULDING & CO. LIMITED; SMITH, IAN, KEITH; HEINICKE, GRANT, WAYNE) 24 April 1997 (1997-04-24) abstract page 2, line 29 - page 3, line 6; claim 30	1,11-15, 17
X	WO 01/95902 A (RESPIRATORIUS AB; SKOGVALL, STAFFAN) 20 December 2001 (2001-12-20) page 2, lines 10-26 page 12, line 14 - page 13, line 7 page 141, line 11; claim 2	1,4,15, 17
X	WO 02/36113 A (RESPIRATORIUS AB; SKOGVALL, STAFFAN) 10 May 2002 (2002-05-10) abstract page 2, lines 9-31 page 37, line 14 - page 38, line 6 page 76, lines 1-3 page 144, line 28; claim 2	1,4,15, 17
X	WO 02/36114 A (RESPIRATORIUS AB; SKOGVALL, STAFFAN) 10 May 2002 (2002-05-10) abstract page 10, line 36 - page 11, line 28 page 49, lines 11-13 page 109, line 26; claim 2	1,4,15, 17
X	WO 95/01096 A (SHAPIRO, HOWARD, K) 12 January 1995 (1995-01-12) claims 27,30	1,3,15, 17
X	WO 98/11923 A (BAYLOR COLLEGE OF MEDICINE; GIULIAN, DANA, J) 26 March 1998 (1998-03-26) abstract page 6, lines 29-31 page 21, line 17 - page 22, line 5 page 56, line 1 - page 57, line 5; example 10 figure 26B	1,3,15

-/--

INTERNATIONAL SEARCH REPORT

International Application No
 /GB2005/001031

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 2005/041964 A (ARAKIS LTD; BREW, JOHN; BANNISTER, ROBIN, MARK; BAXTER, ANDREW, DOUGLA) 12 May 2005 (2005-05-12) the whole document	1, 11-17
A	----- MANTEGANI, SERGIO ET AL: "An easy entry to (1S, 2S) and (1R, 2R)-threo-Ifenprodil" SYNTHETIC COMMUNICATIONS, 30(19), 3543-3553 CODEN: SYNCAV; ISSN: 0039-7911, 2000, XP008054955 the whole document	1, 17
X	----- WO 03/097073 A (ASTION DEVELOPMENT A/S; WEIDNER, MORTEN, SLOTH) 27 November 2003 (2003-11-27) abstract page 4, lines 1-16 page 9, lines 23-29 page 16, line 15 - page 17, line 7; claims 2, 12, 26; examples 26, 49, 158	1-6, 8-13, 15, 17
X	----- WO 03/092617 A (COMBINATORX, INCORPORATED; JOST-PRICE, EDWARD, ROYDON; MANIVASAKAM, PA) 13 November 2003 (2003-11-13) abstract page 3, lines 5-9 page 6, line 15 - page 7, line 14; claim 6	1, 6, 15, 17
X	----- US 5 264 459 A (CHELMICKA-SCHORR ET AL) 23 November 1993 (1993-11-23) the whole document	1, 3, 15
P, X	----- WO 2004/091540 A (THERAQUEST BIOSCIENCES, LLC; BABUL, NAJIB) 28 October 2004 (2004-10-28) abstract paragraphs '0030! - '0038!, '0065!, '0066!, '0095! - '0101!; claims 1, 20	1, 11-15, 17
P, X	----- US 2005/049256 A1 (LORTON DIANNE ET AL) 3 March 2005 (2005-03-03) paragraphs '0010!, '0011!, '0013!, '0022!, '0056!, '0063!; claims 1, 7, 11-15, 17, 25, 26	1, 2, 5, 9, 15, 17
P, X	----- WO 2005/014044 A (BOEHRINGER INGELHEIM INTERNATIONAL GMBH; BOEHRINGER INGELHEIM PHARMA G) 17 February 2005 (2005-02-17) abstract; claims 1, 23	1, 4, 15, 17
E	----- WO 2005/034871 A (INVERSEON, INC; BOND, RICHARD, A) 21 April 2005 (2005-04-21) paragraph '0135!; claims 40, 41	1, 4, 15, 17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2005/001031

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

1-17 (partially) as far as relating to inventions 1,4,12
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-17 (partially)

Use of bufeniode for the manufacture of a medicament for the treatment or prevention of a condition associated with T-cell proliferation or that is mediated by pro- and/or anti-inflammatory cytokines, and in particular a disease selected from the group consisting of rheumatoid arthritis, osteoarthritis or osteoporosis, chronic demyelinating disease such as multiple sclerosis, respiratory diseases such as asthma or chronic obstructive pulmonary disease, inflammatory bowel disease (IBD) such as ulcerative colitis or Crohn's disease, dermatological conditions such as psoriasis, scleroderma or atopic dermatitis, dental diseases such as periodontal disease or gingivitis, diabetic nephropathy, lupus nephritis, IgA nephropathy or glomerulonephritis, systemic lupus erythomatosus (SLE), graft vs host disease, a pain condition is chronic pain such as chronic back pain, malignant pain, chronic headache (including migraine and cluster headaches) or arthritic pain, pain conditions including acute pain such as post-operative pain, post-traumatic pain or acute disease-induced pain and neuropathic pain.

2. claims: 1-17 (partially)

Use of denopamine for the manufacture of a medicament for the treatment or prevention of a condition as specified under invention 1.

3. claims: 1-17 (partially)

Use of fenoterol for the manufacture of a medicament for the treatment or prevention of a condition as specified under invention 1.

4. claims: 1-17 (partially)

Use of ifenprodil for the manufacture of a medicament for the treatment or prevention of a condition as specified under invention 1.

5. claims: 1-17 (partially)

Use of isoxsuprine for the manufacture of a medicament for the treatment or prevention of a condition as specified under invention 1.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

6. claims: 1-17 (partially)

Use of labetalol for the manufacture of a medicament for the treatment or prevention of a condition as specified under invention 1.

7. claims: 1-17 (partially)

Use of medroxalol for the manufacture of a medicament for the treatment or prevention of a condition as specified under invention 1.

8. claims: 1-17 (partially)

Use of mesuprine for the manufacture of a medicament for the treatment or prevention of a condition as specified under invention 1.

9. claims: 1-17 (partially)

Use of nylidrin for the manufacture of a medicament for the treatment or prevention of a condition as specified under invention 1.

10. claims: 1-17 (partially)

Use of protokylol for the manufacture of a medicament for the treatment or prevention of a condition as specified under invention 1.

11. claims: 1-17 (partially)

Use of ractopramine for the manufacture of a medicament for the treatment or prevention of a condition as specified under invention 1.

12. claims: 1-17 (partially)

Use of ritodrine for the manufacture of a medicament for the treatment or prevention of a condition as specified under invention 1.

13. claims: 1-17 (partially)

Use of salmefamol for the manufacture of a medicament for the treatment or prevention of a condition as specified under invention 1.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

14. claims: 1-17 (partially)

Use of sulfinalol for the manufacture of a medicament for
the treatment or prevention of a condition as specified
under invention 1.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

/GB2005/001031

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03092689	A	13-11-2003	AU 2003229977 A1	17-11-2003
			BR 0309684 A	01-03-2005
			CA 2485115 A1	13-11-2003
			CN 1649589 A	03-08-2005
			EP 1501510 A1	02-02-2005
			JP 2005529139 T	29-09-2005
			US 2005222205 A1	06-10-2005
US 3542870	A	24-11-1970	AT 278750 B	10-02-1970
			BE 709012 A	16-05-1968
			CH 485658 A	15-02-1970
			DE 1668930 A1	16-09-1971
			DK 120400 B	24-05-1971
			ES 349044 A1	16-08-1969
			FI 48067 B	28-02-1974
			FR 6087 M	04-06-1968
			FR 6934 M	05-05-1969
			GB 1146139 A	19-03-1969
			SE 349020 B	18-09-1972
			SU 456406 A3	05-01-1975
			YU 4668 A	31-10-1978
WO 02078670	A	10-10-2002	EP 1370240 A1	17-12-2003
WO 9944610	A	10-09-1999	AU 3260099 A	20-09-1999
			CA 2321685 A1	10-09-1999
			EP 1059923 A1	20-12-2000
			JP 2002505287 T	19-02-2002
			US 6538008 B1	25-03-2003
			ZA 9901745 A	06-09-1999
WO 9944640	A	10-09-1999	AT 266420 T	15-05-2004
			AU 753079 B2	10-10-2002
			AU 2632999 A	20-09-1999
			CA 2321687 A1	10-09-1999
			DE 69917230 D1	17-06-2004
			DE 69917230 T2	25-05-2005
			EP 1058559 A1	13-12-2000
			ES 2220047 T3	01-12-2004
			JP 2002505306 T	19-02-2002
			ZA 9901744 A	13-09-1999
			WO 9714415	A
US 6194000 B1	27-02-2001			
WO 0195902	A	20-12-2001	AU 2566301 A	24-12-2001
			AU 2566401 A	24-12-2001
			WO 0195903 A1	20-12-2001
WO 0236113	A	10-05-2002	AU 1288802 A	15-05-2002
WO 0236114	A	10-05-2002	AU 1117602 A	15-05-2002
WO 9501096	A	12-01-1995	AU 692454 B2	11-06-1998
			AU 7214494 A	24-01-1995
			CA 2166383 A1	12-01-1995
			EP 0707446 A1	24-04-1996
			JP 8512055 T	17-12-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

/GB2005/001031

Patent document cited in search report	A	Publication date	Patent family member(s)	Publication date
WO 9811923	A	26-03-1998	AU 738509 B2	20-09-2001
			AU 4589497 A	14-04-1998
			CA 2265896 A1	26-03-1998
			EP 1051195 A1	15-11-2000
			JP 2002504988 T	12-02-2002
<hr/>				
WO 2005041964	A	12-05-2005	NONE	
<hr/>				
WO 03097073	A	27-11-2003	AU 2003260279 A1	02-12-2003
			CA 2482746 A1	27-11-2003
			CN 1646143 A	27-07-2005
			EP 1496917 A1	19-01-2005
			JP 2005529151 T	29-09-2005
<hr/>				
WO 03092617	A	13-11-2003	AU 2003228819 A1	17-11-2003
<hr/>				
US 5264459	A	23-11-1993	NONE	
<hr/>				
WO 2004091540	A	28-10-2004	NONE	
<hr/>				
US 2005049256	A1	03-03-2005	NONE	
<hr/>				
WO 2005014044	A	17-02-2005	NONE	
<hr/>				
WO 2005034871	A	21-04-2005	WO 2005035731 A2	21-04-2005
<hr/>				